Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v3-EN
Language French English
Date Updated 2021-03-24 2021-03-24
Drug Identification Number 02204266 02204266
Brand name DEXAMETHASONE-OMEGA DEXAMETHASONE-OMEGA
Common or Proper name Dexamethasone Sodium Phosphate Injection USP Dexamethasone Sodium Phosphate Injection USP
Company Name OMEGA LABORATORIES LIMITED OMEGA LABORATORIES LIMITED
Ingredients DEXAMETHASONE PHOSPHATE DEXAMETHASONE PHOSPHATE
Strength(s) 4MG 4MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRA-ARTICULAR INTRALESIONAL INTRAMUSCULAR INTRAVENOUS SOFT TISSUE INJECTION INTRA-ARTICULAR INTRALESIONAL INTRAMUSCULAR INTRAVENOUS SOFT TISSUE INJECTION INTRA-ARTICULAR INTRALESIONAL INTRAMUSCULAR INTRAVENOUS SOFT TISSUE INJECTION INTRA-ARTICULAR INTRALESIONAL INTRAMUSCULAR INTRAVENOUS SOFT TISSUE INJECTION
Packaging size 5 x 5mL vial / fiole 5 x 5mL vial / fiole
ATC code H02AB H02AB
ATC description CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2020-06-18 2020-06-18
Estimated end date Unknown Unknown
Actual end date 2021-03-01 2021-03-01
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments On allocation for Covid. On allocation for Covid.
Health Canada comments